Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: A 30-day follow-up study

Catheterization and Cardiovascular Interventions

Volumn 57, Issue 4, 2002, Pages 497-503

  Kaul, Upendra ^a,j   Gupta, Ripen K ^a   Haridas, Kottaram K ^b   Ramesh, Saligrama S ^c   Sethi, Kamal K ^d   Singh, Balbir ^a   Agarwal, Rajiv ^a   Yadave, Ram D ^a   Ghose, Tapan ^a   Sapra, Rakesh R ^a   Bajaj, Rajiv ^a   Shahi, Madhukar ^e   Bhagwat, Ajit ^f   Kumar, Pramod ^g   Mathews, Omen P ^h   Soni, Pratik K ⁱ  

^a Batra Hospital India   (India)

^b AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Department of Cardiology   (India)

^d SIR GANGA RAM HOSPITAL   (India)

^e ST STEPHEN S HOSPITAL   (India)

^f Kamalnayan Bajaj Hospital   (India)

^g Maharaja Agrasen Hospital   (India)

^h ARMED FORCES MEDICAL COLLEGE   (India)

ⁱ Department of Cardiothoracic Surgery   (India)

^j NONE   (India)

more..

Author keywords

Acute myocardial infarction; Eptifibatide; GP IIb IIIa inhibitors; Primary stenting

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOGRAPHY; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG HALF LIFE; FEASIBILITY STUDY; FLOW RATE; HEART MUSCLE PERFUSION; HUMAN; MAJOR CLINICAL STUDY; MALE; REVASCULARIZATION; THROMBOSIS; TREATMENT OUTCOME; VASCULAR PATENCY;

ADULT; AGED; AGED, 80 AND OVER; BLOOD VESSEL PROSTHESIS IMPLANTATION; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PROSPECTIVE STUDIES; STENTS; TIME FACTORS; VASCULAR PATENCY;

EID: 0036894678     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.10351     Document Type: Article

References (33)

1. serruys PW, de Jaegere P, Kiemeneij F, Macaya L, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colkombo A, Goy JJ, Van-den Huevel P, Delcan J, Morel MH, for the BENESTENT study group. A comparison of balloon expandle stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-495.
2. Fischman DL, Leon MB, Baim D, Schatz RA, Penn I, Detre K, Savage MD, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein P, Fish D, Colombo A, Brinker S, Moses J, Hirschfeld J, Bailey S, Ellis S, Rake R, Goldberg S. A randomised comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994;331:496-501.
3. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Guglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;91:1676-1688.
4. Schomig A, Neumann FJ, Kastrati A, Schulen H, Blasini R, Hadamitzky M, Walter H, Roth EMZ, Richardt G, Alt E, Schmitt C, Ulm U. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 1996;334:1084-1089.
5. Bhatt D, Bertrand ME, Berger PB, L'Allier PP, Moussa I, Moses JW, Dangon GS, Taniuchi M, Lasala JM, Holmes DR, Ellis SG, Topol EJ. Meta analysis of randomised and registry comparison of ticlopidine and clopidogrel after stenting. J Am Coll Cardiol 2002;39:1-8.
6. Coller BS. GP IIb/IIIa antagonists: Pathophysiologic and threapeutic insights from studies of c7E3 Fab. Thromb Haemost 1997;78:730-735.
7. EPIC investigators. Use of the monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angiography. N Engl J Med 1994;330:956-961.
8. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, Ivanhoe R, George BS, Fintel D, Weston M. Randomised trial of coronary intervention with antibody against platelet IIb/lIIa integrilin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-886.
9. Simoons ML, Rutsch W, Vahainian A, Maseri A, Vassanelli C, Jadgej C, Adelman A, deBono DD, Verstraete MK, Swedberg K, Tijssen J, Scholtsman P. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997;349:1429-1435.
10. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
11. Lincoff AM, Califf RM, Moliterno DJ, Ellis SG, Ducas J, Kramer JH, Kleiman NS, Cohen EA, Booth JE, Sapp SK, Cobot CF, Topol EJ, Tcheng JE, Talley JD, Carmori PG, Burton JR, Kelly TA, Ivanc TB, for EPISTENT investigators. Complementary clinical benefits of coronary artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999;341:319-327.
12. ESPRIT investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo controlled trial. Lancet 2000;356:2037-2044.
13. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Bawaz M, Kastrati A, Schomig A. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary artery stents in acute myocardial infarction. Circulation 1999;98:2695-2701.
14. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek BH, Moses JW, Moliterno DJ, Ettron MB, Topol E. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
15. Montalescot G, Barrapan A, Wittenberg O, Ecollan P, Elhadao S, Villain P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton P, for the ADMIRAL investigators. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-1903.
16. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, Strony J, Techeng JE, for the ESPRIT investigators. Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial - A randomised controlled trial. JAMA 2001;285:2468-2473.
17. TIMI study group. The thrombolysis in myocardial infarction (TIMI) trial: Phase I findings. N Engl J Med 1985;312:932-936.
18. Gibson CM, Cannon CD, Doley WL, Dodge JT Jr, Alexander B Jr, Marble SJ, Mc Cabe CH, Raymond L, Fortim T, Poole WK, Braunwald E. TIMI Frame count: A quantitative method of assessing coronary artery flow. Circulation 1996;96:879-888.
19. Christopher CP, Gibson CM, Cannon CD, Murphy SA, Ryan KA, Mesley R, Marble SJ, McCabe FH, Van de Werf F and Braunwald E. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125-130.
20. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madone O, Eijgelshoven M, Lansky AJ, O'Neill WW, Morice MC. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999;341:1949-1956.
21. Kaul U, Singh B, Sudan D, Sapra R, Yadave RD, Ghose T, Dixit NS. Primary stenting in acute myocardial infarction: A 30-day follow-up study. Cathet Cardiovasc Intervent 1999;46:4-10.
22. Ghose T, Sapra R, Sudan D, Isser H, Kachru R, Singh B, Kaul U. Primary stenting in acute myocardial infarction in the abciximab era. Ind Heart J 2000;52:712.
23. IMPACT-II investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II. Lancet 1997;349:1422-1428.
24. PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndrome. N Engl J Med 1998;339:436-443.
25. Isser HS, Kaul U, Singh B, Sapra R, Kachru R, Ghose T, Sudan D, Ganguly A, Dixit NS. Experience with small molecule GP IIb/IIIa inhibitor eptifibatide during percutaneous coronary intervention. Ind Heart J 2001;53:594.
26. Ohman EM, Kleinman NS, Gacioch S, Worley SJ, Navetta FL, Talley JD, Anderson V, Ellis SJ, Cohen MD, Spriggs D, Miller M, Kerieake D, Yakabov S, Kitt MM, Sigmon ICN, Califf RM, Krucoff MW, Topol E, for the IMPACT-AMI investigators. Combined accelerated tissue plasminogen activator and glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction: Results of a randomised, placebo controlled dose ranging trial. Circulation 1997;95:846-854.
27. Cutlip DE, Core CJ, Irons D, Kalaria V, Le M, Cronmiller H, Caufield L, Pomerantz RM, Ling FS. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedural outcome. Am J Cardiol 2001;88:62-64.
28. Suryapranata H, Vanit Hof AWS, Hoorntje JCA, deBoer MJ, Zijlstra F. Randomised comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation 1998;97:2502-2505.
29. Savcic M, Hauert J, Bachmann F, Wyld PJ, Geudelin B, Cariou R. Clopidogrel loading dose regimens: Kinetic profile of pharmacodynamic response in healthy subjects. Semin Thrombo Haemost 199925:15-19.
30. Helft G, Osende JI, Worthley SG, Zaman AG, Rodriguez OJ, Lev EI, Faroukh ME, Fuster V, Badimon JJ, Chesbro JH. Acute antithrombotic effect of a front loaded regimen of clopidogrel in patients with atherosclerosis on aspirin. Arterioscler Thromb Vasc Biol 2000;20:2316-2321.
31. Pache J, Kastrati A, Mehilli J, Gawaz M, Neumann FJ, Seyfarth M, Hall D, Braun S, Dirscinger J, Schomig A. Clopidogrel therapy in patients undergoing coronary stenting: Value of a high-loading dose regimen. Cathet Cardiovasc Intervent 2002;55:436-441.
32. Scarborough RM, Kleiman NS, Philips DS. Platelet glycoprotein IIb/IIIa antagonists: What are the relevant issues concerning their pharmacology and clinical use? Circulation 1999;100:437-439.
33. Topol EJ, Mark DB, Lincoff AB, Cohen E, Burton J, Kleiman N, Talley D, Sapp S, Booth J, Cabot CF, Anderson KM, Califf RM, for the EPISTENT investigators. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicenteric randomised trial. Lancet 1999;354:2019-2024.